ArticleDigestive diseases and sciences2026
Cystic Fibrosis Heterozygosity as a Risk Factor for Post-ERCP Pancreatitis: Implications for ERCP Risk Stratification in the Cosmos Cohort.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsEndoscopic retrograde cholangiopantography (ERCP) is widely utilized but carries a risk of post-ERCP pancreatitis (PEP), a major source of morbidity, mortality, and healthcare costs. Although known risk factors exist, the impact of cystic fibrosis (CF) and cystic fibrosis transmembrane conductance regulator (CFTR)-related biology remains incompletely understood. CF affects ~ 30,000 individuals in the U.S. and often involves hepatobiliary disease requiring ERCP. To this end, we aim to determine whether CF heterozygosity carries an elevated risk of PEP following ERCP.
methodsAn analysis was conducted using patient data obtained from the Epic Cosmos cohort, a large-scale population health research platform developed by Epic Systems Corporation. Cosmos aggregates approximately 300 million patient records from participating centers. We included patients undergoing their first ERCP and who required at least one year of prior clinical observation. CF carrier status and CF diagnosis were ascertained using diagnostic codes. PEP was defined as a diagnosis of non-gallstone pancreatitis within 14 days post-ERCP. Multivariable logistic regression and entropy balancing were used for adjustment.
resultsA retrospective analysis of 364,707 patients undergoing 593,660 ERCPs. Of these, 1,074 ERCPs were compared to controls. CF carrier patients were more likely to be female (65.9% vs. 53.9%), older, have prior ERCP (54.0% vs. 39.1%), receive rectal indomethacin (21.1% vs. 14.4%), but less likely to have cholangitis (9.9% vs. 19.6%). The unadjusted PEP rate was significantly higher in CF carriers (40.4% vs. 11.3%, OR = 5.33, p < 0.001). After adjustment, CF carrier status was associated with increased PEP risk (logistic regression: adjusted OR = 2.34, 95% CI: 2.03-2.69; entropy balancing: adjusted OR = 2.13, 95% CI: 1.83-2.48).
conclusionCF heterozygosity status is independently associated with a substantially increased risk of post-ERCP pancreatitis, suggesting that CFTR dysfunction may heighten pancreatic vulnerability during ERCP. Clinically, CF carriers may represent an underrecognized high-risk group who could benefit from more intensive pre-procedural risk assessment and optimized prophylactic strategies.
Indexed as
Identifiers
42166038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.